I was just in Leipzig for the in-person portion of BIO-Europe 2022 that ran from October 24th to 26th. It is great to be back in person at BIO-Europe, the last event I was able to attend was in Hamburg in 2019. There were more than 4,500 attendees representing more than 2,000 companies here currently, which made it a great place to create new partnerships for NeoNeuro and NeoVentures. It was a fantastic experience to be in a place that was able to accommodate over 20,000 meetings, a huge shout-out to everyone that was involved in setting this meeting up.
A great thing about BIO-Europe is that they have a virtual event as well that is running November 2nd to 4th. During this time there is a large library of content that showcases the companies that attended in person and all the program sessions. Additionally, there are still opportunities to connect via Zoom meetings in the comfort of your own home. So, if you missed the in-person session and would like to connect with me regarding potential partnership, please don’t hesitate to reach out by email (firstname.lastname@example.org) for a meeting.
Leipzig is a beautiful city, and I am happy that I have been able to visit it for this conference. If you ever have the chance to visit, I do suggest it. There is a lot of history here, with world-class research facilities (more than 30 research institutions). I have had a lot of great meetings already and am looking forward to the ones still to come online in the future. It was a great place where I can work on practicing my German as well, danke Leipzig für eine tolle Zeit! I hope to see everyone again in-person at BIO-Europe 2023 in Munich.
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.